Brian R. Wynne, M.D.

Medicine Development Lead for Dolutegravir
ViiV Healthcare, Research Triangle Park, NC, USA

Disclosure(s): ViiV Healthcare: I am an employee, Stocks/Bonds

Poster(s):

• 1267 - Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results from the TANGO and SALSA Studies
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET